便携式高效空气净化器改善COPD健康的随机临床试验:CLEAN AIR研究
该盲法随机对照试验纳入116名中重度COPD既往吸烟者,比较活性与假便携式高效空气净化器6个月的效果。意向性分析中总SGRQ评分无显著差异,但活性组症状亚量表、呼吸症状、中度急性加重率和急救药物使用均显著降低;符合方案分析中主要结局SGRQ也出现显著差异,依从性高且室内时间长者获益更明显。
要点
- 活性空气净化器可降低COPD患者中度急性加重率(IRR 0.32)和急救药物使用(IRR 0.54)
- 依从性>80%的符合方案分析中,SGRQ总分显著改善(β -4.76)
- 室内停留时间更长的参与者更可能从空气净化器治疗中获益
核心结论
- 这是首个在COPD既往吸烟者中开展的环境干预研究,显示便携式高效空气净化器可能带来健康获益,尤其在依从性高和室内时间长的人群中。
研究设计与样本
- 盲法随机对照试验,纳入116名中重度COPD既往吸烟者,随机接受活性或假便携式高效空气净化器并随访6个月。
- 主要结局为6个月圣乔治呼吸问卷(SGRQ)变化;次要结局包括急性加重风险、呼吸症状、急救药物使用和6分钟步行距离(6MWD)。
- 意向性分析纳入所有受试者,符合方案分析纳入依从参与者(空气净化器使用率>80%)。
主要发现
- 意向性分析中总SGRQ评分无统计学显著差异,但活性组SGRQ症状亚量表降幅更大(β -7.7,95%CI -15.0至-0.37)。
- 活性组呼吸症状(呼吸困难、咳嗽和咳痰量表)改善更明显(β -0.8,95%CI -1.5至-0.1)。
- 活性组中度急性加重发生率更低(发生率比0.32,95%CI 0.12-0.91),急救药物使用更少(发生率比0.54,95%CI 0.33-0.86),均P<0.05。
- 符合方案分析中,活性组与假组主要结局SGRQ差异有统计学意义(β -4.76,95%CI -9.2至-0.34),中度急性加重风险、呼吸症状量表和6MWD也有显著差异。
- 室内停留时间更长的参与者更可能获得治疗获益。
关键数值与推荐
- 纳入标准:既往吸烟者,中度至重度COPD。
- 依从性定义:空气净化器使用率>80%。
- 主要结局:6个月SGRQ评分变化。
临床怎么用
- 对于中重度COPD既往吸烟者,可考虑推荐使用便携式高效空气净化器以改善呼吸症状和减少中度急性加重。
- 应强调高依从性(使用率>80%)和增加室内停留时间以最大化潜在获益。
局限性
- 总SGRQ评分在意向性分析中未达统计学显著差异。
- 研究仅纳入既往吸烟者,结果可能不适用于当前吸烟者。
- 随访时间为6个月,长期效果未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Indoor particulate matter is associated with worse chronic obstructive pulmonary disease (COPD) outcomes. It remains unknown whether reductions of indoor pollutants improve respiratory morbidity. Objectives: To determine whether placement of active portable high-efficiency particulate air cleaners can improve respiratory morbidity in former smokers. Methods: Eligible former smokers with moderate-to-severe COPD received active or sham portable high-efficiency particulate absolute air cleaners and were followed for 6 months in this blinded randomized controlled trial. The primary outcome was 6-month change in St. George's Respiratory Questionnaire (SGRQ). Secondary outcomes were exacerbation risk, respiratory symptoms, rescue medication use, and 6-minute-walk distance (6MWD). Intention-to-treat analysis included all subjects, and per-protocol analysis included adherent participants (greater than 80% use of air cleaner). Measurements and Main Results: A total of 116 participants were randomized, of which 84.5% completed the study. There was no statistically significant difference in total SGRQ score, but the active filter group had greater reduction in SGRQ symptom subscale (β, -7.7 [95% confidence interval (CI), -15.0 to -0.37]) and respiratory symptoms (Breathlessness, Cough, and Sputum Scale, β, -0.8 [95% CI, -1.5 to -0.1]); and lower rate of moderate exacerbations (incidence rate ratio, 0.32 [95% CI, 0.12-0.91]) and rescue medication use (incidence rate ratio, 0.54 [95% CI, 0.33-0.86]) compared with sham group (all P < 0.05). In per-protocol analysis, there was a statistically significant difference in primary outcome between the active filter versus sham group (SGRQ, β -4.76 [95% CI, -9.2 to -0.34]) and in moderate exacerbation risk, Breathlessness, Cough, and Sputum Scale, and 6MWD. Participants spending more time indoors were more likely to have treatment benefit. Conclusions: This is the first environmental intervention study conducted among former smokers with COPD showing potential health benefits of portable high-efficiency particulate absolute air cleaners, particularly among those with greater adherence and spending a greater time indoors.
引用
- Hansel NN, Putcha N, Woo H, et al. Randomized Clinical Trial of Air Cleaners to Improve Indoor Air Quality and Chronic Obstructive Pulmonary Disease Health: Results of the CLEAN AIR Study. Am J Respir Crit Care Med. 2022. PMID: 34449285. doi:10.1164/rccm.202103-0604OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。